TRAVERSE and Mood: Small Improvements, and a Diagnosis That Barely Existed

Of 5,204 men randomised in TRAVERSE, 2,643 — 50.8% — had significant depressive symptoms. Only 49 men, 1.5%, met rigorous criteria for late-life-onset low-grade persistent depressive disorder.[1] That gap between how many men feel low and how many have a diagnosable persistent depressive disorder is the most useful thing this sub-study produced, and it comes before any question about whether treatment works.

What was tested

The depression analysis was nested in the TRAVERSE cardiovascular safety trial: randomised, placebo-controlled, double-blind, across 316 sites.[1]

• Participants: men aged 45–80, with two fasting testosterone levels below 300 ng/dL, one or more hypogonadal symptoms, and cardiovascular disease or increased risk of it.
• Intervention: 1.62% transdermal testosterone gel or placebo gel.
• Three subgroups analysed: men with rigorously defined low-grade persistent depressive disorder (LG-PDD, previously called dysthymia); all men with significant depressive symptoms (PHQ-9 score >4); and all randomised men.
• Outcomes: proportions meeting criteria for LG-PDD or significant depressive symptoms, plus changes in depressive symptoms, energy, sleep quality and cognition.[1]

Measuring four separate things — mood, energy, sleep, cognition — is what makes the result readable. They did not all move.

What it found

In men with rigorously defined LG-PDD (n=49): no significant difference in any outcome measure between testosterone and placebo. The authors note this possibly reflects low statistical power.[1]

That caveat is real and should be carried with the finding. Forty-nine men is a small group, and a null result in a small group is weak evidence of no effect rather than evidence of no effect.

In men with significant depressive symptoms (n=2,643) and in all randomised men (n=5,204):

Testosterone was associated with modest but significantly greater improvements in mood and energy, but not in cognition or sleep quality.[1]

Two of four domains moved. Two did not.

What "modest" is doing in that sentence

The authors' own conclusion uses "small": TRT is associated with small improvements in mood and energy in hypogonadal men with and without significant depressive symptoms.[1]

This is consistent rather than surprising. The T Trials found slightly better mood and lower severity of depressive symptoms on testosterone, alongside no benefit for vitality. Two large trials, a decade apart, both landing on "real but small" for mood is about as replicated as this field gets.

The sleep result also replicates a negative — covered in does testosterone improve sleep.

The finding that matters most clinically

Depressive symptoms are common in middle-aged and older men with hypogonadism. Low-grade persistent depressive disorder is uncommon.[1]

Half of the men in a trial selected for low testosterone and hypogonadal symptoms screened positive for significant depressive symptoms. Fewer than one in sixty had the rigorously defined disorder.

The implication is not that the other men were fine. It is that "I feel flat" is an extremely common presentation in this population, that it is usually not a persistent depressive disorder, and that testosterone produces a small improvement in it — not a resolution. A man whose depressive symptoms are severe or persistent needs the depression assessed on its own terms, not folded into a hormone conversation.

How it fits the rest of the programme

TRAVERSE's sub-studies do not point the same way, which is the strongest argument for reading them individually rather than as a verdict:

• Sexual function — desire improved, erectile function did not
• Anaemia — a real benefit, at real numbers
• Bone — more fractures on treatment, not fewer
• Prostate — no significant difference
• Mood — small improvements in mood and energy; nothing in cognition or sleep

The main cardiovascular result sits in the TRAVERSE main trial.

What this does not establish

1. It is not a trial of testosterone for depression. Every participant had low testosterone and cardiovascular disease or risk. Nothing here speaks to treating depression in men with normal testosterone.
2. The LG-PDD null is underpowered by the authors' own statement.[1] It does not license the claim that testosterone is ineffective in dysthymia.
3. Statistical significance across 5,204 men is not the same as a difference a man would notice. "Modest" and "small" are the authors' words, and they belong in any honest summary.

Bottom line

TRAVERSE found that low mood is very common in hypogonadal men, that a diagnosable persistent depressive disorder is not, and that testosterone produces small improvements in mood and energy while changing nothing measurable about sleep or cognition.

Testosterone is not an antidepressant, and it was not tested as one. If mood is the main reason someone is considering therapy, the realistic expectation is a small lift — and the depression itself still needs to be looked at directly.

References

1 source

1. Bhasin S, Seidman S, Travison TG, et al. Depressive Syndromes in Men With Hypogonadism in the TRAVERSE Trial: Response to Testosterone-Replacement Therapy. J Clin Endocrinol Metab. 2024;109(7):1814–1826. doi:10.1210/clinem/dgae026 · PMID 38205962